HER2 expression by breast cancer cells in 15–20% of cancer patients prompted the development of HER2-targeted therapies [8–10], which are an important pillar for the treatment of HER2-positive breast cancer patients and significantly improved patient survival [9]. This evidence concerns the gene ERBB2 and cancer.